Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

← catalyst calendar

NCT05152147

Sponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →. With BeOne Medicines LTD, BeOne Pharmaceutical Co., Ltd..

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
920actual
Sites
227
Countries
Argentina, Australia, Belgium +30

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2021-12-02actualWhen the study began enrolling
Primary completion2026-07-31estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2027-07-31estimatedThe whole study's end, after follow-up
First posted2021-12-09actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-07-17actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Gastric Neoplasms
  • Gastroesophageal Adenocarcinoma
  • Esophageal Adenocarcinoma

Interventions

  • Drug: Zanidatamab — also filed as ZW25, JZP598, ZIIHERA®
  • Drug: Tislelizumab
  • Drug: Trastuzumab — also filed as Herceptin®
  • Drug: Capecitabine
  • Drug: Oxaliplatin
  • Drug: Cisplatin
  • Drug: 5-Fluorouracil

Primary outcomes

what the primary-completion date above is the date OF
Progression-free survival (PFS) by BICR
measured Up to 2.5 years
Overall survival
measured Up to 3.5 years

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed